What is the recommended first‑line therapy for nodular lymphocyte‑predominant Hodgkin lymphoma in limited (stage I–II) versus advanced (stage III–IV) disease?

Nodular Lymphocyte-Predominant Hodgkin Lymphoma: First-Line Therapy Recommendations

Limited-Stage Disease (Stage I-II)

For stage IA NLPHL without risk factors, treat with 30 Gy involved-site radiotherapy (ISRT) alone 1, 2. This is the only scenario where NLPHL differs from classical Hodgkin lymphoma treatment, and this approach achieves approximately 90% 8-year progression-free survival with near 100% overall survival 3.

For all other limited-stage presentations (stage IB-II or stage IA with risk factors such as B symptoms, >2 nodal sites, or variant pattern histology), treat NLPHL identically to classical Hodgkin lymphoma using combined-modality therapy:

• 2 cycles of ABVD followed by 20 Gy ISRT for early favorable disease 4, 2
• 4 cycles of ABVD followed by 30 Gy ISRT for early unfavorable disease (presence of bulky mediastinal disease, B symptoms, ESR ≥50, or >3 involved nodal regions) 2, 4

The 2018 ESMO guidelines 4 represent the most current standard, recommending ISRT over the older involved-field radiotherapy (IFRT), though this has not been validated in prospective randomized trials. The evidence consistently shows 10-year progression-free survival rates exceeding 70% and overall survival rates above 90% with these combined-modality approaches 3.

Key Considerations for Limited-Stage Disease:

• Risk factors that determine treatment intensity include: bulky mediastinal disease (mediastinal mass ratio >0.33), B symptoms, elevated ESR (≥50 with B symptoms or ≥30 without), and multiple involved nodal regions (>3 by NCCN/EORTC criteria) 5
• The question of omitting radiotherapy in PET-negative patients after chemotherapy remains controversial. Multiple trials (RAPID, H10) demonstrate superior progression-free survival with combined-modality treatment even in interim PET-negative patients 4. Chemotherapy alone may be offered only to highly selected individuals where late RT toxicity risks clearly outweigh benefits 4
• Completely resected stage IA disease may require no further treatment, particularly in pediatric patients 6

Advanced-Stage Disease (Stage III-IV)

For advanced-stage NLPHL, the optimal chemotherapy regimen is not definitively established, but treat with standard chemotherapy protocols used for classical Hodgkin lymphoma or aggressive B-cell lymphomas 1, 3.

The most commonly used approaches include:

• 6-8 cycles of ABVD (most widely used in North America) 7
• 6-8 cycles of BEACOPP escalated (preferred by German Hodgkin Study Group for patients <60 years, showing superior outcomes but higher toxicity) 2
• R-CHOP (rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone) appears effective given CD20 expression on malignant cells 3, 6

Consolidation radiotherapy is confined to patients with residual disease after chemotherapy 2. In patients achieving complete metabolic response after BEACOPP escalated, RT can be omitted for residual masses <2.5 cm 2.

Critical Distinctions for Advanced-Stage NLPHL:

• Unlike classical HL, NLPHL malignant cells consistently express CD20, making rituximab-containing regimens biologically rational 1, 3
• Advanced-stage NLPHL has higher relapse rates and risk of transformation to aggressive B-cell non-Hodgkin lymphoma compared to early stages 1, 8
• Always obtain repeat biopsy at relapse to exclude transformation to aggressive NHL, which occurs more frequently than historically recognized 1

Treatment Selection Algorithm:

1. Stage IA without risk factors → 30 Gy ISRT alone
2. Stage IB-II favorable → 2 cycles ABVD + 20 Gy ISRT
3. Stage I-II unfavorable → 4 cycles ABVD + 30 Gy ISRT
4. Stage III-IV → 6-8 cycles ABVD or BEACOPP escalated (age <60) or R-CHOP, with RT only for residual disease

Common Pitfalls to Avoid:

• Do not treat stage IA NLPHL without risk factors with chemotherapy—radiotherapy alone is sufficient and avoids unnecessary toxicity 1, 2
• Do not assume NLPHL relapse is the same histology—transformation to aggressive B-cell lymphoma occurs in a substantial proportion and requires biopsy confirmation before salvage therapy 1
• Do not overlook fertility preservation counseling before alkylating agent-based chemotherapy or pelvic radiotherapy 4, 5
• Do not use extended-field radiotherapy—modern ISRT provides equivalent disease control with reduced toxicity 4

The overarching principle in NLPHL management is minimizing treatment-related toxicity while maintaining excellent disease control, as patients more often die from therapy-related late effects than lymphoma-related complications 8. The excellent overall survival (nearly mirroring general population life expectancy) mandates careful consideration of long-term toxicity risks including secondary malignancies, cardiac disease, and infertility 9, 10.